| European Case Law Identifier: | ECLI:EP:BA:2003:T059098.20030430 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 30 April 2003 | ||||||||
| Case number: | T 0590/98 | ||||||||
| Application number: | 90914225.9 | ||||||||
| IPC class: | A61K 51/00 | ||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | B | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | New cores for technetium radiopharmaceuticals | ||||||||
| Applicant name: | Amersham plc | ||||||||
| Opponent name: | The Du Pont Merck Pharmaceutical Company | ||||||||
| Board: | 3.3.02 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: | |||||||||
| Keywords: | Admissibility of appeal (yes): no evidence of transfer of business Main request: disclaimer not acceptable under Articles 84 and 123(2) EPC; no reason to suspend the proceedings until decision of the Enlarged Board of Appeal in cases G 0001/03 and G 0002/03 Auxiliary requests 1 to 4: not admissible as reformatio in peius Apportionment of costs (no) |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t980590eu1.html
Date retrieved: 17 May 2021